Literature DB >> 32635858

Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells.

Anup Kumar Singh1, Ayushi Verma1, Akhilesh Singh1, Rakesh Kumar Arya1, Shrankhla Maheshwari1,2, Priyank Chaturvedi1, Mushtaq Ahmad Nengroo1, Krishan Kumar Saini1,2, Achchhe Lal Vishwakarma3, Kavita Singh4, Jayanta Sarkar5, Dipak Datta1,2.   

Abstract

Drug resistance is one of the trademark features of Cancer Stem Cells (CSCs). We and others have recently shown that paucity of functional death receptors (DR4/5) on the cell surface of tumour cells is one of the major reasons for drug resistance, but their involvement in the context of in CSCs is poorly understood. By harnessing CSC specific cytotoxic function of salinomycin, we discovered a critical role of epigenetic modulator EZH2 in regulating the expression of DRs in colon CSCs. Our unbiased proteome profiler array approach followed by ChIP analysis of salinomycin treated cells indicated that the expression of DRs, especially DR4 is epigenetically repressed in colon CSCs. Concurrently, EZH2 knockdown demonstrated increased expression of DR4/DR5, significant reduction of CSC phenotypes such as spheroid formation in-vitro and tumorigenic potential in-vivo in colon cancer. TCGA data analysis of human colon cancer clinical samples shows strong inverse correlation between EZH2 and DR4. Taken together, this study provides an insight about epigenetic regulation of DR4 in colon CSCs and advocates that drug-resistant colon cancer can be therapeutically targeted by combining TRAIL and small molecule EZH2 inhibitors.

Entities:  

Keywords:  EZH2; apoptosis; cancer stem cells; death receptors; salinomycin

Mesh:

Substances:

Year:  2020        PMID: 32635858      PMCID: PMC7889220          DOI: 10.1080/15592294.2020.1789270

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  64 in total

1.  ER stress causes rapid loss of intestinal epithelial stemness through activation of the unfolded protein response.

Authors:  Jarom Heijmans; Jooske F van Lidth de Jeude; Bon-Kyoung Koo; Sanne L Rosekrans; Mattheus C B Wielenga; Marc van de Wetering; Marc Ferrante; Amy S Lee; Jos J M Onderwater; James C Paton; Adrienne W Paton; A Mieke Mommaas; Liudmila L Kodach; James C Hardwick; Daniël W Hommes; Hans Clevers; Vanesa Muncan; Gijs R van den Brink
Journal:  Cell Rep       Date:  2013-03-28       Impact factor: 9.423

2.  New Spisulosine Derivative promotes robust autophagic response to cancer cells.

Authors:  Asha Ganesher; Priyank Chaturvedi; Rohit Sahai; Sanjeev Meena; Kalyan Mitra; Dipak Datta; Gautam Panda
Journal:  Eur J Med Chem       Date:  2020-01-02       Impact factor: 6.514

3.  Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.

Authors:  Sha Hu; Lili Yu; Zhimin Li; Yi Shen; Jing Wang; Jing Cai; Lan Xiao; Zehua Wang
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

4.  Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene.

Authors:  T Yoshida; A Maeda; N Tani; T Sakai
Journal:  FEBS Lett       Date:  2001-11-02       Impact factor: 4.124

5.  Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.

Authors:  Siân Rizzo; Jenny M Hersey; Paul Mellor; Wei Dai; Alessandra Santos-Silva; Daniel Liber; Louisa Luk; Ian Titley; Craig P Carden; Garry Box; David L Hudson; Stanley B Kaye; Robert Brown
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

Review 6.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

Review 7.  Stem cells and cancer; the polycomb connection.

Authors:  Merel E Valk-Lingbeek; Sophia W M Bruggeman; Maarten van Lohuizen
Journal:  Cell       Date:  2004-08-20       Impact factor: 41.582

8.  p53 upregulates death receptor 4 expression through an intronic p53 binding site.

Authors:  Xiangguo Liu; Ping Yue; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

9.  ER-Stress-Induced Differentiation Sensitizes Colon Cancer Stem Cells to Chemotherapy.

Authors:  Mattheus C B Wielenga; Selcuk Colak; Jarom Heijmans; Jooske F van Lidth de Jeude; Hans M Rodermond; James C Paton; Adrienne W Paton; Louis Vermeulen; Jan Paul Medema; Gijs R van den Brink
Journal:  Cell Rep       Date:  2015-10-08       Impact factor: 9.423

10.  Cancer stem cell drugs target K-ras signaling in a stemness context.

Authors:  A K Najumudeen; A Jaiswal; B Lectez; C Oetken-Lindholm; C Guzmán; E Siljamäki; I M D Posada; E Lacey; T Aittokallio; D Abankwa
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

View more
  8 in total

1.  TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.

Authors:  Sha Zhou; Jianhong Peng; Liuniu Xiao; Caixia Zhou; Yujing Fang; Qingjian Ou; Jiayi Qin; Mengzhong Liu; Zhizhong Pan; Zhenlin Hou
Journal:  Cell Death Dis       Date:  2021-05-08       Impact factor: 8.469

2.  CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5.

Authors:  Mushtaq A Nengroo; Shrankhla Maheshwari; Akhilesh Singh; Ayushi Verma; Rakesh K Arya; Priyank Chaturvedi; Krishan K Saini; Anup K Singh; Abhipsa Sinha; Sanjeev Meena; Annapurna Gupta; Anjali Mishra; Jayanta Sarkar; Dipak Datta
Journal:  Cell Death Dis       Date:  2021-05-08       Impact factor: 8.469

Review 3.  The long and short non-coding RNAs modulating EZH2 signaling in cancer.

Authors:  Sepideh Mirzaei; Mohammad Hossein Gholami; Kiavash Hushmandi; Farid Hashemi; Amirhossein Zabolian; Israel Canadas; Ali Zarrabi; Noushin Nabavi; Amir Reza Aref; Francesco Crea; Yuzhuo Wang; Milad Ashrafizadeh; Alan Prem Kumar
Journal:  J Hematol Oncol       Date:  2022-03-02       Impact factor: 17.388

Review 4.  Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells.

Authors:  Valdenizia R Silva; Luciano de S Santos; Rosane B Dias; Claudio A Quadros; Daniel P Bezerra
Journal:  Cancer Commun (Lond)       Date:  2021-11-17

5.  Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression.

Authors:  Junhui Yu; Kui Yang; Jianbao Zheng; Pengwei Zhao; Jie Xia; Xuejun Sun; Wei Zhao
Journal:  Cell Death Dis       Date:  2022-04-21       Impact factor: 9.685

Review 6.  Salinomycin as a potent anticancer stem cell agent: State of the art and future directions.

Authors:  Dan Qi; Yunyi Liu; Juan Li; Jason H Huang; Xiaoxiao Hu; Erxi Wu
Journal:  Med Res Rev       Date:  2021-11-16       Impact factor: 12.388

7.  Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG).

Authors:  Chen Lyu; Lili Wang; Birgit Stadlbauer; Elfriede Noessner; Alexander Buchner; Heike Pohla
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

8.  Horizontal transfer of the stemness-related markers EZH2 and GLI1 by neuroblastoma-derived extracellular vesicles in stromal cells.

Authors:  Aranzazu Villasante; Amandine Godier-Furnemont; Alberto Hernandez-Barranco; Johanne Le Coq; Jasminka Boskovic; Hector Peinado; Jaume Mora; Josep Samitier; Gordana Vunjak-Novakovic
Journal:  Transl Res       Date:  2021-07-02       Impact factor: 10.171

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.